Sapphire Medical Clinics and Dendrite Clinical Systems have launched the UK Medical Cannabis Registry, an initiative that is designed to rapidly expand the evidence base for medical cannabis in the UK and decrease the cost of access for patients. The launch will collect and analyse clinical information on patients taking medical cannabis treatments for all recognised eligible conditions.
“I am very pleased to report that demand for the Dendrite Web-Registry platform has reached an all-time high” Dr Peter Walton, Managing Director of Dendrite Clinical System. “We’re receiving new orders for new national and international registries every few days now – for surgical registries, medical registries, rare disease registries, medical device registries and Coronavirus Registries (for a range of Community, National, International and Global Covid-19 Registries).”
Sapphire Medical Clinics and Dendrite Clinical Systems have established the UK’s first national UK’s first comprehensive medical cannabis patient registry - UK Medical Cannabis Registry. The UK Medical Cannabis Registry will be the first of its kind covering all conditions for which there is evidence of clinical efficacy of medical cannabis. The formation of the registry means that real world evidence, cited as a key barrier to wider patient prescriptions by NHS England, will now be available on request to the medical community for analysis.
The British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS), in conjunction with Dendrite Clinical Systems, is delighted to announce the release of the First UK National Flap Registry (UKNFR) Report. The UKNFR, which was launched in August 2015, collects information on all major free and pedicled flap operations carried out in the UK.
Dendrite Clinical Systems, the publisher of Bariatric News, has announced the publication of the Bariatric News Industry and Product Guide 2019 – a comprehensive A-Z guide to companies, products and services within the bariatric and metabolic specialty. 
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 39 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite enters international ‘CoviDiab’ collaborative research initiative
Dendrite Clinical Systems’ innovative “Intellect Web” software has been chosen by an international group of 17 leading diabetes experts from the multidisciplinary Diabetes Surgery Summit (DSS), as the platform on which the CoviDiab project will establish a Global Registry to collect new cases of diabetes in patients with COVID-19. The aim of the CoviDiab Registry is to understand the extent and the characteristics of the manifestations of diabetes in patients with COVID-19, and the best strategies for the treatment and monitoring of affected patients, during and after the pandemic.
“We are honoured that the CoviDiab Investigators have chosen our International Web-Registry software platform for this important project,” said Dr Peter Walton, Managing Director of Dendrite Clinical Systems. “This is just one of several COVID-19 registries we are developing in conjunction with teams of international researchers all over the world. As a company, we are proud to be playing a key role in helping to combat this devastating disease.”
“Diabetes is one of the most prevalent chronic diseases and we are now realising the consequences of the inevitable clash between two pandemics,” said Professor Francesco Rubino, Professor of Metabolic Surgery at the School of Life Course Sciences, King’s College London, UK and co-lead investigator of the CoviDiab project. “Given the short period of human contact with this new coronavirus, the exact mechanism by which the virus influences glucose metabolism is still unclear and we don’t know whether the acute manifestation of diabetes in these patients represent classic type 1, type 2 or possibly a new form of diabetes.”
The registry, which will be expanded to include patients with pre-existing diabetes who present with severe acute metabolic disturbance, may also be used to investigate the epidemiologic features and pathogenesis of Covid-19–related diabetes and to gain clues regarding appropriate care for patients during and after the course of Covid-19.
“We don’t yet know the magnitude of the new onset diabetes in COVID-19 and if it will persist or resolve after the infection; and if so, whether or not or COVID-19 increases risk of future diabetes,” explained Paul Zimmet, Professor of Diabetes at Monash University in Melbourne, Honorary President of the International Diabetes Federation and co-lead investigator in the CoviDiab project. “By establishing this Global Registry, we are calling on the international medical community to rapidly share relevant clinical observations that can help answer these questions.”
The CoviDiab Registry will be launched in the coming months. For more information, please click here
